Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news was a marked upturn in revenue and a transition to positive GAAP net income. The company’s GAAP revenue was $62.5 million, driven by strong uptake of its anemia therapy Vafseo and resilient sales from Auryxia, its longstanding kidney drug. Net income reached $0.2 million, sharply higher than the consensus loss estimate and last year’s $8.6 million GAAP net loss. With Vafseo’s commercial rollout in full swing and no major generic competition yet affecting Auryxia, Akebia turned in a quarter that reflected robust momentum, despite caution ahead for one of its main revenue drivers.
Source: Analyst estimates for the quarter provided by FactSet.
Akebia Therapeutics develops and markets therapies for people living with chronic kidney disease. Its key commercial products are Vafseo, an oral medicine that treats anemia in adults undergoing dialysis, and Auryxia, a tablet for managing high blood phosphate and iron deficiency in kidney disease patients.
Source Fool.com
Akebia Therapeutics Inc. Stock
With 10 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 6 € there is potential for a 215.62% increase which would mean more than doubling the current price of 1.9 € for Akebia Therapeutics Inc..
